Patients worldwide treated with Memokath™ since first launch
Countries in which Memokath™ is currently used
Urinary tract obstructions are debilitating illnesses causing pain, suffering and health risk to patients of all ages. Though some patients can be treated pharmaceutically, many are left with the dire choice between surgery and catheters both of which risk impacting their lives permanently through undesired side-effects, complications, discomfort and a dependency on medical attention.
Pnn Medical was founded in 1987 with the mission of improving quality of life for people suffering from urinary tract obstructions by developing and bringing to market the most minimally invasive solutions causing fewest side-effects, least discomfort and lowest degree of medical dependency enabling patients to continue living their lives to the widest possible degree.
Pnn is an acronym for “primum non nocere” (first do no harm) – the Hippocratic oath sworn by medical graduates across the world to put patient welfare at the highest of priorities.
Pnn Medical celebrates 30 years of unwavering dedication to the development and marketing of the most minimally invasive and safe treatment options to help improve the quality of life for people suffering from urinary tract obstructions.
The continued expansion of the Memokath™ range in Japan paves the way for a cooperation with German medical device producer, Carl Storz, whose portable flexible cystoscope is used to effectively insert Memokath™ 028 Prostate in private clinics without use of X-ray.
Following strong external interest, and a continually increasing demand for the Memokath™ and Memocore™ range in existing and new markets, Emteva™ is sold to British medical device producer, Hunter Urology Ltd. to narrow down the focus to development and marketing of metallic stents.
Following an extensive phase of R&D with physicists and oncologists at Aalborg University Hospital in Denmark Memocore™ is launched as the first metallic fiducial marker inserted through the urethra used for external beam radiation therapy as alternative to the standard gold marker.
To simplify and strengthen marketing communication and signal the intention of moving forward as one unified company, Engineers & Doctors Wallsten Medical A/S changes name to Pnn Medical A/S and launches new brand identity and logo symbolizing the stent’s way through an obstructed urinary tract.
The continued success of Memokath™ and interest in the market for minimally invasive treatments forms the basis of the merger with Swiss medical device producer, Wallsten Medical SA, founded and owned by Hans Wallsten – inventor of the revolutionizing cardiovascular stent, Wallstent.
The success of Memokath™ paves way for the development of new minimally invasive treatment options within urinary tract obstructions. Engineers & Doctors develops and launches the world’s first 100% biodegradable intermittent catheter for women Emteva™.
Continued efforts within R&D and uncompromising drive to develop and bring to market the most efficient and minimally invasive treatments for urinary tract obstructions makes way for the second-generation metallic stent Memokath™ 028 Prostate, aimed at treating prostatic enlargement.
To improve the standard of care and quality of life for the growing population of people suffering from prostatic enlargement, the first-generation metallic stent Prostakath is launched after development cooperation with Herlev University Hospital in Copenhagen, Denmark.
Engineers & Doctors A/S founded by polymer engineer Erik Othel-Jacobsen and medical doctor Henrik Harboe to improve the quality of life for people suffering from urinary tract obstructions by developing and marketing the most minimally invasive and safe treatment methods.
Pnn Medical cooperates with acclaimed urologists and oncologists across the world by means of R&D, clinical development, execution of clinical trials as well as training and education via workshops and reference centers. With more than 150 clinical studies published from prominent medical centers worldwide the Memokath™ product range is probably the best clinically documented urological stent on the market. More than five new studies on the Memokath™ range are currently underway, expected to be published during 2020 and 2021 adding to the wealth of substantial clinical and health economic data supporting the use of Memokath™.
Pnn Medical A/S 2019 All rights reserved